Market Overview

Friedreich's Ataxia | A Pipeline Analysis Report 2018 | Technavio


Technavio has announced their latest pipeline analysis report on the Friedreich's
ataxia market
. The report includes a detailed analysis of the
pipeline molecules under investigation within the defined data
collection period to treat Friedreich's ataxia.

This press release features multimedia. View the full release here:

Technavio has published a new report on the drug development pipeline for Friedreich's ataxia, inclu ...

Technavio has published a new report on the drug development pipeline for Friedreich's ataxia, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report by Technavio
presents a detailed analysis of the market, including regulatory
framework, drug development strategies, recruitment strategies, and key
companies that are expected to play an essential role in the growth of
the market in the future.

This report is available at a USD 1,000 discount for a limited time
market snapshot before purchasing

Friedreich's ataxia: Market overview

Friedreich's ataxia can be defined as a rare genetic disease that is
caused by a defect (mutation) in a gene labeled FXN, which carries the
genetic code for a protein called frataxin. The mutation in the FXN gene
is the main cause of Friedreich's ataxia. The symptoms of this genetic
disorder include difficulty in walking and poor balance, dysarthria,
shortness of breath, and loss of normal reflexes, especially for knees
and ankles. The treatment of Friedreich's ataxia includes physical
therapy, surgery, and medications.

According to a senior market research analyst at Technavio, "Friedreich's
ataxia usually starts in childhood, and it worsens over a period, which
leads to impairments in muscle coordination. People with Friedreich's
ataxia can also have a form of hypertrophic cardiomyopathy, which
enlarges and weakens the heart muscle."

Friedreich's ataxia: Segmentation analysis

This pipeline analysis report segments the familial adenomatous
polyposis market based on therapies employed (monotherapy and
combination therapy), RoA (oral), therapeutic modality (small molecule,
gene therapy, protein, unsaturated fatty acid, and Recombinant fusion
protein), targets (lipid peroxidation, DAAO, erythropoietin receptor,
NAD(P)H dehydrogenase (quinone) 1, Nrf2 activator, Nrf2, and sirtuin 1
protein), MoA (Frataxin protein replacement, gene replacement, lipid
peroxidation inhibitor, DAAO inhibitor, erythropoietin receptor agonist,
gene upregulation, NAD(P)H dehydrogenase (quinone) 1 modulator, NF-kappa
B inhibitor, Nrf2 activator and sirtuin 1 protein stimulator) and
recruitment status (recruiting, completed, and active, not recruiting).
It provides an in-depth analysis of the prominent factors influencing
the market, including drivers, opportunities, trends, and
industry-specific challenges.

Based on therapeutic modality, more than 54% of the molecules that are
being investigated for the treatment of Friedreich's ataxia are small

Looking for more information on this market? Request
a free sample report

Technavio's sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio's comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team

View Comments and Join the Discussion!